Esperion Receives the US FDA’s Approval for Nexlizet (Non-Statin LDL-Cholesterol Lowering Therapy)

 Esperion Receives the US FDA’s Approval for Nexlizet (Non-Statin LDL-Cholesterol Lowering Therapy)

Esperion Receives the US FDA’s Approval for Nexlizet (Non-Statin LDL-Cholesterol Lowering Therapy)

Shots:

  • The approval is based on P-III FDC LDL-C lowering program assessing Nexlizet (bempedoic acid and ezetimibe) vs PBO and the safety data of Nexletol (bempedoic acid) in pivotal P-III LDL-C lowering program with the existing ezetimibe safety profile
  • The P-III study resulted in lowering the LDL-C by 38% when added on to maximally tolerated statins and is well tolerated. The approval follows the approval of Nexletol (bempedoic acid) received on Feb 21, 2020 with its anticipated availability in the US in Mar’2020
  • Nexlizet (PO, qd) is the first non-statin LDL-cholesterol lowering combination therapy, indicated as an adjunct to diet and maximally tolerated statin therapy for HeFH/ established ASCVD in patients requiring additional lowering of LDL-C with its expected availability in the US in July’2020

Click here ­to­ read full press release/ article | Ref: Esperion | Image: Seek Vector Logo

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post